Copaxone 40 mg 3 Times a Week FDA-Approved

Jan 29 2014

Tired of daily Copaxone 20 mg injections for multiple sclerosis?  A new option is now available.  FDA just approved 40 mg dose three times a week.

The GALA trial studied Copaxone 40 mg (double dose) three times a week vs. placebo in 1404 patients.  Copaxone 40 mg three times a week reduced new relapses 34% and reduced MRI activity with contrast 45%.  Safety of Copaxone 40 mg appears comparable to 20 mg dose.  In fact, a lower amount of immediate post-injection reactions were seen in the GALA 40 mg trial.  Previous studies had demonstrated a 29% reduction of relapses with Copaxone 20 mg daily.

If interested in switching to 40 mg three times a week, discuss with your healthcare provider.

BY: Barry Singer, MD DATE: January 29, 2014 TOPIC: MS Research News